After 40-year odyssey, first drug for aggressive MS wins FDA approval

first_img Log In | Learn More By Ron Winslow March 28, 2017 Reprints Forty years ago, one of Dr. Stephen Hauser’s first patients was a young Harvard Law School graduate and White House aide with a case of multiple sclerosis that raced like a brush fire through her brain. She quickly lost her ability to speak, swallow, and breathe. She got married in a wheelchair in her hospital room, tethered to breathing and feeding tubes and dressed in her wedding gown.“We had nothing to treat her with,” recalled Hauser, now director of the Weill Institute for Neurosciences at the University of California, San Francisco. It was such a searing moment for the young doctor, then at the beginning of his neurology training, that he decided to dedicate his career to MS research. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. [email protected] Dr. Stephen Hauser in his office at the University of California, San Francisco. Elizabeth D. Herman for STAT @ronwinslow GET STARTED About the Author Reprints What is it? Health After 40-year odyssey, first drug for aggressive MS wins FDA approval Ron Winslow What’s included? Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Tags biotechnologydrug developmentneurologypharmaceuticalspolicylast_img


Leave a Reply

Your email address will not be published. Required fields are marked *